Should health-care systems pay for replacement therapy in patients with alpha(1)-antitrypsin deficiency? A critical review and cost-effectiveness analysis
(Q33860662)
scientific article
scientific article
Language:
Current Data About
Should health-care systems pay for replacement therapy in patients with alpha(1)-antitrypsin deficiency? A critical review and cost-effectiveness analysis
| (P31) |
(Q13442814)
|
||||||||||||||||
| (P304) |
875-880
|
||||||||||||||||
| (P407) |
(Q1860)
|
||||||||||||||||
| (P433) |
3
|
||||||||||||||||
| (P478) |
117
|
||||||||||||||||
| (P577) |
Wednesday, March 1, 2000
|
||||||||||||||||
| (P921) |
(Q1754768)
|
||||||||||||||||
| (P1433) |
(Q5093377)
|
||||||||||||||||
| (P1476) |
"Should health-care systems pay for replacement therapy in patients with alpha(1)-antitrypsin deficiency? A critical review and cost-effectiveness analysis" (language: en)
|
||||||||||||||||
| (P2093) |
Alkins SA
O'Malley P
|
other details